Benchmark lowered the firm’s price target on Omnicell (OMCL) to $40 from $62 and keeps a Buy rating on the shares, which dropped 15% yesterday as investors got the “yips” following a reduction in FY25 non-GAAP EBITDA and EPS guidance to reflect the impact of tariffs, primarily with China. In the firm’s revised FY25 non-GAAP EBITDA, it now reflects net tariff impact $40M versus our prior model and assumes a lingering $15M tariff impact on FY26, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL:
- Omnicell’s Resilience and Growth Potential: A Justified Buy Rating by Bill Sutherland
- Hold Rating for Omnicell Amid Tariff Challenges and Competitive Pressures
- Omnicell Reports Strong Q1 2025 Financial Results
- Omnicell’s Earnings Call: Mixed Sentiments Amid Growth
- Omnicell lowers FY25 non-GAAP EPS view to $1.00-$1.65 from $1.65-$1.85